UroGen Pharma URGN Non Cash New Lease Liabilities
Non Cash New Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept urgn:NonCashNewLeaseLiabilities.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's non cash new lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's non cash new lease liabilities?
- UroGen Pharma (URGN) reported non cash new lease liabilities of $60K in Q1 2026.
- How has UroGen Pharma's non cash new lease liabilities changed year-over-year?
- UroGen Pharma's non cash new lease liabilities decreased by 97.1% year-over-year, from $2.05M to $60K.
- What is the long-term trend for UroGen Pharma's non cash new lease liabilities?
- Over 2 years (2022 to 2025), UroGen Pharma's non cash new lease liabilities has grown at a 85.2% compound annual growth rate (CAGR), from $2.17M to $7.43M.
- What does non cash new lease liabilities mean?
- Represents the initial recognition of lease liabilities for new operating or finance leases that do not involve immediate cash outflows. This metric is essential for understanding the company's off-balance-sheet financing commitments and long-term operational obligations.